Dublin, Ireland, 28th November, 2016: DS Biopharma (DS), a privately held drug discovery and development company, today announced that it will present an overview of the Company at the Piper Jaffray 28th Annual Healthcare Conference on Wednesday the 30th of November in New York.
Dr. John Climax, Executive Chairman of DS will present from 9.50am (EST) at the Lotte New York Palace hotel, 455 Madison Avenue, New York.
About DS Biopharma
DS Biopharma, headquartered in Dublin, Ireland, is a privately held drug discovery and development company working on new medicines that improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. DS has developed a proprietary bioactive lipid technology platform. The Company is developing Oral DS107 for moderate to severe atopic dermatitis and Topical DS107 for mild to moderate atopic dermatitis. Recruitment for two separate Phase IIb studies with these products will begin in December 2016. In addition, the Company is developing DS109 for the treatment of inflammatory skin disorders. Clinical Development of this product began in November 2016.
DS Biopharma: firstname.lastname@example.org, +35312933590